The authors investigate whether and how pricing and promotional activities influence prescription choice behavior using a comprehensive panel of physicians and data on competitive price and promotional activities. The authors find that physicians are characterized by fairly limited price sensitivity, detailing and samples have a mostly informative effect on physicians, and physicians with a relatively large number of Medicare or health maintenance organization patients are less influenced by promotion than other physicians are.
Get full access to this article
View all access options for this article.
References
1.
BerndtErnst R., BuiLinda T., ReileyDavid H., and UrbanGlen L. (1994), “The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry,” Working Paper No. 19-94, Program on the Pharmaceutical Industry, Massachusetts Institute of Technology.
2.
BonomaThomas V. (1982), “Major Sales: Who Really Does the Buying?”Harvard Business Review, 60 (May/June), 111–19.
3.
ChamberlainGary (1980), “Analysis of Covariance with Qualitative Data,”Review of Economic Studies, 47, 225–38.
4.
GönülFüsun F., CarterFranklin, and WindJerry (2000), “What Kinds of Patients and Physicians Value Direct-to-Consumer Advertising of Prescription Drugs?”Health Care Management Science, 3, 215–26.
5.
HellersteinJudith K. (1997), “The Demand for Post-patent Prescription Pharmaceuticals,”RAND Journal of Economics.
6.
HurwitzMark A., and CavesRichard E. (1988), “Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals,”Journal of Law and Economics, 31 (October), 299–320.
7.
KamakuraWagner A., and RussellGary J. (1989), “A Probabilistic Choice Model for Market Segmentation and Elasticity Structure,”Journal of Marketing Research, 26 (November), 379–90.
KrapfelRobert E.Jr. (1985), “An Advocacy Behavior of Organizational Buyers' Vendor Choice,”Journal of Marketing, 49 (4), 51–59.
10.
LefflerKeith B. (1981), “Persuasion or Information? The Economics of Prescription Drug Advertising,”Journal of Law and Economics, 24 (April), 45–74.
11.
MarksLawrence J., and KaminsMichael A. (1988), “The Use of Product Sampling and Advertising: Effects of Sequence of Exposure and Degree of Advertising Claim Exaggeration on Consumers' Belief Strength, Belief Confidence, and Attitudes,”Journal of Marketing Research, 25 (August), 266–81.
12.
McFaddenDaniel (1974), “Conditional Logit Analysis of Qualitative Choice Behavior,” in Frontiers of Economics, ZarembkaP., ed. New York: Academic Press, 105–42.
13.
MilgromPaul, and RobertsJ. (1982), “Limit Pricing and Entry Under Incomplete Information: An Equilibrium Analysis,”Econometrica, 50 (March), 443–59.
14.
MilgromPaul, and RobertsJ. (1986), “Price and Advertising Signals of Product Quality,”Journal of Political Economy, 94 (4), 796–821.
15.
MillerRobert H., and LuftHarold S. (1994), “Managed Care Plan Performance Since 1980: A Literature Analysis,”Journal of the American Medical Association, 271 (19), 1512–19.
16.
MitraAnusree, and LynchJohn G.Jr. (1995), “Toward A Reconciliation of Market Power and Information Theories of Advertising Effects on Price Elasticity,”Journal of Consumer Research, 21 (March), 644–59.
17.
NelsonPaul (1970), “Information and Consumer Behavior,”Journal of Political Economy, 20 (March/April), 311–29.
18.
NelsonPaul (1974), “Advertising as Information,”Journal of Political Economy, 24 (July/August), 729–45.
19.
NerloveMark, and ArrowKenneth J. (1962), “Optimal Advertising Policy Under Dynamic Conditions,”Economica, (May), 129–42.
20.
NewhouseJoseph P. (1993), Free for All? Lessons from the RAND Health Insurance Experiment.Cambridge, MA: Harvard University Press.
21.
PhRMA (1994), “Pharmaceutical Marketing Practices: Questions and Answers,” paper presented at the PhRMA Marketing Practices Committee, Washington, DC (September).
22.
Van ZandtWilliam (1993), “How Much Sampling Is Enough?”Pharmaceutical Executive, (September), 92–96.
23.
ZieglerMichael G., LewPauline, and SingerBrian C. (1995), “The Accuracy of Drug Information from Pharmaceutical Sales Representatives,”Journal of the American Medical Association, 273 (16), 1296–98.
